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Received November 7, 2015; accepted February 23, 2016AbstractBackground: Transcatheter device closure of postmyocardial infarction ventricular septal defect (PMIVSD) is less invasive than surgical repair.
However, its feasibility, timing, outcome, and prognostic factors remain unclear.
Methods: This was a multicenter, retrospective cohort study. Between February 2012 and July 2015, a total of 10 (8 male and 2 female) patients
with PMIVSD undergoing attempted device closure were enrolled retrospectively. The procedures were performed under general anesthesia with
fluoroscopic and transesophageal echocardiographic guidance.
Results: The patients enrolled in the study were in the age range 50e85 years (median age of 76.5 years). The interval from infarction to device
closure ranged from 6e147 days, with the median of 12 days. A total of 13 devices were implanted in 10 patients. There were five Amplatzer
muscular ventricular septal defect occluders, four Amplatzer septal occluders, three Amplatzer PMIVSD occluders and one Amplatzer vascular
plug II. Complications included transient ventricular tachycardia in three patients, device embolization in one patient, and tracheal bleeding in
one patient. No procedure-related death, stroke, or cardiac tamponade was noted. During follow-up, two patients died of heart failure and two
patients died of sepsis. Overall, subjects with age  80 years, systolic blood pressure  90 mmHg, and procedure time 180 minutes were
significant predictor factors for mortality. All patients with the interval of infarction to device closure >12 days survived.
Conclusion: Our findings indicate that transcatheter device closure of PMIVSD is technically feasible, safe, and effective to reduce the shunt.
The crucial prognostic factors were ascertained to be age  80 years, systolic blood pressure  90 mmHg, and procedure time 180 minutes.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Post myocardial infarction ventricular septal defect
(PMIVSD) usually occurs within the 1st week following
infarction, with an incidence of 0.2e0.34% since the advent of
reperfusion therapy.1,2 If the defect remains unrepaired, it has
a high fatality rate of more than 90%.1 Surgical repair is
suggested by using current guidelines to avoid abrupt cardio-
vascular collapse; however, such intervention still possesses asevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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surgeons typically prefer to wait at least 2e4 weeks for the
firm scar to form over the margins of defect, which allows for
better anchoring of suture and patch material.2,8 Many patients
die during this waiting period prior to surgery. Transcatheter
device closure of PMIVSD is less invasive and can decrease
the mortality rate to 14.3e42%.8e13 However, its feasibility,
timing, outcome, and prognostic factors remain unclear.
2. Methods2.1. Study designThis is a multicenter, retrospective, cohort study and
conducted in accordance with the Declaration of Helsinki
and ethic regulation in our hospital.14 From February 2012 to
July 2015, a total of 10 patients (8 males and 2 females) with
PMIVSD undergoing attempted device closure were enrolled
retrospectively. Their age range was 50e85 years, with the
median of 76.5 years. The interval from infarction to VSD
found ranged from 2 to 146 days, with the median of 7.5
days. The interval from infarction to device closure ranged
from 6 to 147 days, with the median of 12 days. The de-
mographic data of these patients is summarized in Table 1.
Vasoactiveeinotropic score was calculated for the total
equivalent dose of inotrope including dopamine, dobutamine,
epinephrine, norepinephrine, and milrinone.15,16 The Model
of End-Stage Liver Disease Excluding International
Normalized Ratior (MELD-XI) score was calculated using
creatinine and total bilirubin according to the following
formula: 5.11 ln (bilirubin mg/dL) þ 11.76 ln (creati-
nine mg/dL) þ 9.44, as an index of multiorgan system
dysfunction.17Table 1
Patient demographics before procedure.
No. Age
(y)
Sex Occluded
coronary artery
Infarction
territory
(wall)
Previous
surgery
VIS
score
IABP EC
1 76 M RCA Inferior VSD repair 14.8 þ d
2 50 M LAD Anterior CABG/
VSD repair
d d d
3 80 M LAD Anterior VSD repair NA þ d
4 61 M LAD Anterior d 60.6 þ d
5 77 M LAD Anterior d d d d
6 71 M RCA Inferior CABGþ
Mitral repair
97.6 þ þ
7 85 F LAD þ RCA Anterior d 5.1 þ d
8 80 F LAD Anterior d 9.1 d d
9 70 M LAD þ LCX Anterior d 6.5 þ d
10 77 M RCA þ LCX Inferior d d d d
AMI¼ acute myocardial infarction; BP (S/D/M)¼ blood pressure (systolic/diasto
membrane oxygenation; F¼ female; IABP¼ intra-aortic balloon pump; Interva
LCX¼ left circumflex artery; M¼male; MELD-XI¼Model for End-stage Live
proBNP¼N-terminal of the prohormone brain natriuretic peptide; PCI¼ percuta
acutemyocardial infarction; VIS¼ vasoactiveeinotrope score.2.2. ProcedureInformed consent was obtained from all patients or their
family members. The device closure procedure was described
in a previous report and briefly as related below. Cefazolin
(1 g) was given to the patients as a prophylatic antibiotic.18,19
Vascular access was obtained from the right internal jugular
vein and the right femoral artery. We performed the procedure
under general anesthesia, with fluoroscopic and trans-
esophageal echocardiographic guidance. Routine right and left
heart catheterizations were done for the evaluation of pul-
monary to system flow ratio (Qp/Qs). A Judkins right catheter
was advanced retrogradely to cross the VSD. A 0.035-inch
glide wire was advanced through the Judkins catheter into
the pulmonary artery or superior vena cava, which was
captured with a snare catheter through the jugular vein to
establish an arteriovenous loop. A 24- or 34-mm compliant
low-pressure sizing balloon (St. Jude Medical) was used to
measure the stretched size of VSD and was subsequently
exchanged for an appropriate sized delivery sheath. The size
selection of deployed device was about 1.5e2 times the size
of the stretched balloon. Ultimately, the device selection was
based on the size of the device. The priority was the
Amplatzer muscular VSD occluder (up to 18 mm), Amplatzer
PMIVSD occluder (up to 24 mm, available since November
2013), and then atrial septal occluder (up to 40 mm, if bigger
device needed). The Amplatzer vascular plug II was used if
the defect was the long-tunnel type. If the left ventriculogram
fully opacified the right ventricle after the 1st device im-
plantation, indicating a large residual shunt, we would sub-
sequently try to deploy a second device. After the procedure,
oral aspirin, 100 mg daily, was prescribed for at least 6
months.MO BP (S/D/M)
(mmHg)
Interval
AMI to VSD
found (d)
Interval
AMI to device
closure (d)
NT-proBNP
(pg/mL)
MELD-XI
score
112/62/75 9 75 NA 10.7
101/78/90 6 79 9290 7.8
90/41/60 3 10 NA 29.2
103/63/75 71 80 > 35000 35.1
104/67/83 4 10 5120 15.5
74/50/56 9 12 168 35.4
86/35/50 2 8 NA 29.3
82/45/59 4 6 22900 19.1
98/44/66 9 12 2180 8.8
127/75/92 146 147 13101 24.8
lic/mean); CABG¼ coronary artery bypass grafting; ECMO¼ extracorporeal
l¼ interval from AMI to device; LAD¼ left anterior descending artery;
r Disease Excluding International normalized ratio; NA¼ not available; NT-
neous coronary intervention; RCA¼ right coronary artery; Time¼ time after
36 Y.-L. Nie et al. / Journal of the Chinese Medical Association 80 (2017) 34e382.3. StatisticsWe stratified each predictor factor into two groups and used
Fisher’s exact test to correlate them with mortality.
3. Results
The results are summarized in Table 2. A total of 13 de-
vices were successfully implanted in 10 patients (Fig. 1), and 3
patients received two devices (Fig. 2). There were five
Amplatzer muscular ventricular septal defect occluders, four
Amplatzer septal occluders, three Amplatzer PMIVSD
occluders, and one Amplatzer vascular plug II. Three patients
experienced transient ventricular tachycardia when the sheath
crossed the VSD. In Patient 7, the 2nd device (16-mm
Amplatzer muscular VSD occluder) was embolized into the
pulmonary artery, which was successfully retrieved and
replaced with a 30-mm Amplatzer septal occluder. Patient 2
had a large residual shunt with a sign of heart failure and
underwent surgical repair 38 days later. Patient 1 exhibited
bleeding from the endotracheal tube which was resolved by
reversing the anticoagulation effect of heparin by protamine.
There was no cardiac tamponade or stroke. During follow-up,
two patients died of heart failure and another two died of
pneumonia-associated sepsis. There was no late complication
after the procedure. Five patients had good prognosis with
New York Heart Association functional class II. Prediction of
mortality of different factors is summarized in Table 3.
4. Discussion
The main findings of our study include the following. First,
transcatheter device closure of PMIVSD is technically
feasible. All patients received device implantation success-
fully. Second, the device closure procedure is safe without
major complications of procedure-related death, stroke, orTable 2
Results of transcatheter closure of PMIVSD.
No. Qp/Qs VSD
number
VSD size
(mm)
Device type
and size (mm)
Residual
shunta
Fluorosco
time (min
1 2.50 1 8.0 MVSDO (12) Small 25.2
2 2.95 2 4.2 MVSDO (6) Large 168.8
3 2.08 2 17.1, 10.7 ASO (24), VPII (20) Small NA
4 3.57 1 16.1 ASO (24) Moderate 42.8
5 4.67 2 10.8, 10.7 MVSDO (18, 16) Small 40.3
6 2.53 1 26.4 ASO (38) Absent 30.5
7 1.71 3 5.8, 16.8 MVSDO (12),
ASO (30)
Small 138
8 4.09 1 8.6 MVSDO (16)/
PMIVSDO (24)
Small 49.9
9 2.30 1 15.2 PMIVSDO (24) Small 31.1
10 3.4 1 16.2 PMIVSDO (24) Small 29.9
ASO¼Amplatzer septaloccluder; ICU¼ intensive care unit; MVSDO¼muscula
Heart Association; Qp/Qs¼ pulmonary to systemic flow ratio; PMIVSDO¼ postmy
vascular plug; VSD¼ ventricular septal defect; VT¼ ventricular tachycardia.
a Residual shunt measured by color Doppler echocardiography: small¼< 2 mmcardiac tamponade. Third, only one patient had a large re-
sidual shunt, thereby proving that the procedure can effec-
tively reduce the shunt. Fourth, all patients with systolic blood
pressure & 90 mmHg prior to procedure died. All patients
with systolic blood pressure > 90 mmHg survived. It indicates
that blood pressure is a crucial prognostic factor ( p¼ 0.005).
Fifth, all patients with the interval of infarction to device
closure >12 days survived. However, for patients with an in-
terval &12 days, the mortality rate was high (67%). This in-
dicates that intervention at the acute stage carries a high risk.
Some cardiologists suggest that it is necessary to delay device
closure for > 2 weeks after infarction.20 In our opinion, this
does not mean that early intervention should be avoided
because device closure could be a salvage procedure for acute
critical patients. Sixth, patients aged  80 years have a higher
mortality rate than those aged < 80 years (100% vs. 14%,
p¼ 0.033). Seventh, procedure time  180 minutes had a
higher mortality rate than procedure times < 180 minutes
(75% vs. 20%, p¼ 0.048).
Most prognostic factors are not statistically significant
probably because the sample size was quite small. However,
the mortality rate of MELD-XI score  20 was 60% and < 20
was 20%. The result was similar to those in Assenza et al,
indicating that the mortality rate of MELD-XI score  20 was
62%.13
PMIVSDs are often serpiginous and multiple, and balloon
sizing can determine the exact size and shape of VSD, which
are important for device selection and deployment.11 About
half (26/53) of the patients in the UK registry received
balloon sizing.11 We prefer to use balloon sizing to measure
the accurate size of VSD; a compliant low-pressure balloon
is recommended to avoid an enlarged VSD. The size selec-
tion of the deployed device could be 1.5 times the stretched
balloon size in subacute stage. However, it should be at least
1.5e2 times in the acute stage due to the fragile injured
myocardium.py
)
Procedure
time (min)
Complication ICU days Outcome
92 Tracheal
bleeding
15 Survival (NYHA class II)
302 no 3 Survival (NYHA class II)
NA no 15 Died of heart failure at Day 15
140 VT 28 Survival (NYHA class III)
156 VT 3 Survival (NYHA class II)
189 no 16 Died of heart failure at Day 16
355 VT, device
embolization
11 Died of sepsis at Day 11
200 no 8 Died of sepsis at Day 8
75 no 10 Survival (NYHA class I)
70 no 4 Survival (NYHA class II)
r ventricular septal defect occluder; NA¼ not available; NYHA¼New York
ocardial infarction ventricular septal defect occluder; VPII¼ 2nd generation of
; moderate¼ 2e4 mm; large¼> 4 mm.
Fig. 1. (A) Left ventriculogram in patient 1 showing an 8-mm PMIVSD (arrow); (B) a 12-mm Amplatzer muscular VSD occluder was implanted; (C) left
ventriculogram after device implantation showing only small residual shunt. LV¼ left ventriculogram; RV¼ right ventriculogram.
Fig. 2. (A) Left ventriculogram in Patient 5 showing two PMIVSDs (arrow); (B) Two Amplatzer muscular VSD occluders were implanted; (C) left ventriculogram
after device implantation showing only small residual shunt. LV¼ left ventriculogram; RV¼ right ventriculogram.
37Y.-L. Nie et al. / Journal of the Chinese Medical Association 80 (2017) 34e38This study does have certain limitations. First, it was
retrospective in nature, with a small sample size. With the
progression and broader availability of percutaneous coronary
intervention, the incidence of PMIVSD is now quite rare. In
fact, it is difficult to perform a randomized comparison with
surgical repair.Table 3
Prediction of mortality in device closure of PMIVSD.
Factor
Age (y) < 80 :  80
Sex M : F
Infarction territory (wall) Anterior : Inferior
Previous surgical repair of VSD Yes : no
VIS score <15 : 15
IABP Yes : no
ECMO Yes : no
Systolic BP (mmHg)  90 : > 90
Interval between AMI to device closure (d)  12 : > 12
NT-proBNP (pg/mL) < 20000 :  2000
MELD-XI score < 20 :  20
VSD number 1 :  2
Maximum VSD size (mm) < 17 :  17
Residual shunt Absent to Small : Modera
Procedure time (min) < 180 :  180
AMI¼ acute myocardial infarction; BP¼ blood pressure; ECMO¼ extracorpore
M¼male; MELD-XI¼Model for End-stage Liver Disease Excluding Internation
uretic peptide; PMIVSD¼ postmyocardial infarction ventricular septal defect; VISIn conclusion, according to our experience in this study,
transcatheter device closure of PMIVSD is technically feasible,
safe, and effective to reduce the shunt. We found that patients
with age  80 years, systolic blood pressure  90 mmHg,
and procedure time 180 minutes were significant predictor
factors for mortality.Mortality rate p
14% :100% 0.033
25% : 100% 0.133
43% : 33% 1.000
33% : 43% 1.000
29% : 50% 1.000
50% : 25% 0.571
100% : 33% 0.400
100% : 14% 0.005
67% : 0 0.076
0 20% : 50% 1.000
20% : 60% 0.524
33% : 50% 1.000
25% : 100% 0.133
te to large 50% : 0 0.467
20% : 75% 0.048
al membrane oxygenation; F¼ female; IABP¼ intra-aortic balloon pump;
al normalized ratio; NT-proBNP¼N-terminal of the prohormone brain natri-
¼ vasoactiveeinotrope score; VSD¼ ventricular septal defect.
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